阻断肺腺癌细胞A2aR抑制肿瘤相关巨噬细胞迁移及极化

阻断肺腺癌细胞A2aR抑制肿瘤相关巨噬细胞迁移及极化阻断肺腺癌细胞A2aR抑制肿瘤相关巨噬细胞迁移及极化

摘要：

阻断肺腺癌细胞中的A2aR可能是肿瘤免疫治疗的一个重要治疗策略。本文研究了A2aR抑制肝癌细胞内肿瘤相关巨噬细胞（tumor-associatedmacrophages,TAMs）的迁移和极化。我们发现，A2aR在人类肺腺癌培养细胞株A549中高度表达，并通过放化疗促进巨噬细胞的极化。使用A2aR拮抗剂PSB1115能够显著降低A549细胞对巨噬细胞的吸引力和刺激TAMs向免疫抑制M2型突触的方向发展，并使TAMs转变为能够产生细胞毒素的M1型细胞，从而有效抑制肿瘤细胞的生长。结论：此研究表明，抑制A2aR对调节TAMs的免疫代谢，增加消极肿瘤免疫反应并刺激阳性T细胞的产生是一种有效的抑制肺腺癌细胞生长的方法。

关键词：A2aR、肺腺癌、肿瘤相关巨噬细胞、抵制、突触、肿瘤生长。

Abstract:

BlockingA2aRinlungadenocarcinomacellsmaybeanimportanttherapeuticstrategyforcancerimmunotherapy.Thispaperstudiedthemigrationandpolarizationoftumor-associatedmacrophages(TAMs)inhibitedbyA2aRinlivercancercells.WefoundthatA2aRwashighlyexpressedinhumanlungadenocarcinomaculturedcellsA549andpromotedthepolarizationofmacrophagesthroughradiotherapyandchemotherapy.UsingA2aRantagonistPSB1115couldsignificantlyreduceA549cells'attractivenesstomacrophagesandstimulateTAMstodeveloptowardsimmunosuppressiveM2synapses,andtransformTAMsintoM1cellscapableofproducingcytotoxins,effectivelyinhibitingtumorcellgrowth.Conclusion:ThisstudyshowsthatinhibitingA2aRisaneffectivemethodtoregulatetheimmunemetabolismofTAMs,increasenegativetumorimmuneresponse,andstimulatetheproductionofpositiveTcellstoinhibitlungadenocarcinomacellgrowth.

Keywords:A2aR,lungadenocarcinoma,tumor-associatedmacrophages,inhibition,synapse,tumorgrowthInconclusion,thestudysuggeststhatinhibitingA2aRcaneffectivelyregulatetheimmunemetabolismofTAMsandincreasenegativetumorimmuneresponse,leadingtotheinhibitionoflungadenocarcinomacellgrowth.TAMsplayavitalroleinthetumormicroenvironment,andtheirtransitionfromM2cellstoM1cellscanenhancetheproductionofpositiveTcellsthathelpfightagainsttumorcells.TheinhibitionofA2aRcreatesanenvironmentwhereTAMsformimmunosuppressiveM2synapsesthattransformintoM1cellscapableofattackingtumorcellseffectively.ThisstudyhighlightsthepotentialoftargetingA2aRasatherapeuticapproachforlungadenocarcinomatreatment.FuturestudiescanexploretheclinicalapplicationsofA2aRinhibitorsandtheireffectsonothercancertypesInadditiontotargetingA2aR,thereareotherpotentialtherapeuticapproachesforlungadenocarcinomatreatment.Forinstance,immunecheckpointinhibitorshavebeenshowntobeeffectiveinlungcancertreatment.Theseinhibitorsblocktheinteractionbetweencertaincellsurfaceproteins,calledcheckpointreceptors,andtheirligands,whichcansuppresstheimmuneresponsetocancercells.Ipilimumab,nivolumab,pembrolizumab,andatezolizumabaresomeofthecheckpointinhibitorsapprovedforlungcancertreatment.

Anotherpromisingapproachistheuseofchimericantigenreceptor(CAR)T-celltherapy,whichinvolvesgeneticallymodifyingapatient'sT-cellstoexpressreceptorsthatcanrecognizeandattacktumorcells.CAR-Ttherapyhasshownremarkableresultsintreatingbloodcancers,andthereareongoingclinicaltrialsexploringitspotentialuseinsolidtumors,includinglungcancer.

Finally,personalizedmedicineapproaches,suchastumormolecularprofilingandtargetedtherapy,arealsobeingexploredforlungcancertreatment.Theseapproachesinvolveidentifyingspecificmolecularalterationsinapatient'stumorandselectingthemostappropriatetherapybasedonthatinformation.Forinstance,EGFRinhibitorsandALKinhibitorsaretargetedtherapiesapprovedforthetreatmentoflungadenocarcinomathathaveshownsignificantclinicalbenefitsforpatientswiththerespectivemolecularalterations.

Inconclusion,lungadenocarcinomaisacomplexdiseasethatrequiresamultidisciplinaryapproachforeffectivetreatment.TargetingA2aRandotherimmunosuppressivemechanismsinthetumormicroenvironment,aswellasutilizingimmunecheckpointinhibitors,CAR-Ttherapy,andpersonalizedmedicineapproaches,holdgreatpromiseforimprovingpatientoutcomesinthefutureInadditiontotheaforementionedapproaches,thereareseveralotheremergingtherapiesforlungadenocarcinomathatarecurrentlybeinginvestigatedinclinicaltrials.Onesuchapproachistheuseoftumor-targetingviruses,whichselectivelyinfectandreplicatewithincancercells,ultimatelyleadingtotheirdestruction.Anotherpromisingapproachistheuseofbispecificantibodies,whichcansimultaneouslytargettwodifferentproteinsoncancercellstoincreasetheirspecificityandpotency.

Furthermore,recentadvancesingenomicshaveallowedfortheidentificationofnoveltherapeutictargetsinlungadenocarcinoma.Forexample,mutationsintheKEAP1/NRF2pathwayhavebeenassociatedwithincreasedoxidativestressandinflammationintumors,leadingtoresistancetochemotherapyandradiationtherapy.Targetingthispathwaywithsmallmoleculeinhibitorshasshownpromisingresultsinpreclinicalmodelsandiscurrentlybeingevaluatedinclinicaltrials.

Inaddition,immuneevasioninlungadenocarcinomacanalsobemediatedbyalterationsinthetumorcellmetabolism.Specifically,theupregulationofcertainmetabolicpathways,suchasfattyacidsynthesis,cansuppresstheexpressionofimmunegenesandpromotetumorgrowth.Thus,inhibitorsofthesemetabolicpathwaysarebeingexploredaspotentialtherapeuticagents.

Lastly,newtechnologiessuchasliquidbiopsyandcirculatingtumorDNAanalysisofferaminimallyinvasiveapproachtomonitortumorprogressionandresponsetotherapy.Bydetectingspecificmutationsandgenomicalterationsincirculatingtumorcells,thesetoolscanprovidevaluableinformationondiseasestatusandguidetreatmentdecisions.

Insummary,themanagementoflungadenocarcinomarequiresacomprehensiveapproachthatintegratesbothtraditionalandemergingtherapies.Theuseofimmunotherapy,personalizedmedicine,andnoveltargetedagentsofferthepotentialforimprovedoutcomesandincreasedsurvivalforthisdevastatingdisease.Asresearchcont